A clinical case of adult-onset Still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitors

The basis of the clinical picture of adult-onset Still's disease is a triad of symptoms, includingfever, arthralgia/arthritis, and characteristic rash called «Still rash». The first line of therapy includes glucocorticoids, synthetic disease-modifying anti-rheumatic drugs; biological agents, su...

Full description

Bibliographic Details
Main Authors:	R. R. Samigullina, E. A. Vasilenko, V. I. Mazurov
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2019-03-01
Series:	Современная ревматология
Subjects:	adult-onset still's disease interleukin-1 interleukin-6 canakinumab biological agents
Online Access:	https://mrj.ima-press.net/mrj/article/view/892

id	doaj-35a9dd2a6ad846a693bb61b814548d8e
record_format	Article
spelling	doaj-35a9dd2a6ad846a693bb61b814548d8e2021-07-29T09:00:12ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2019-03-01131919410.14412/1996-7012-2019-1-91-942153A clinical case of adult-onset Still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitorsR. R. Samigullina0E. A. Vasilenko1V. I. Mazurov2I.I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaI.I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaI.I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaThe basis of the clinical picture of adult-onset Still's disease is a triad of symptoms, includingfever, arthralgia/arthritis, and characteristic rash called «Still rash». The first line of therapy includes glucocorticoids, synthetic disease-modifying anti-rheumatic drugs; biological agents, such as tumor necrosis factor a inhibitors and interleukin-6 and interleukin-1 inhibitors, are used in standard therapy-resistant cases.https://mrj.ima-press.net/mrj/article/view/892adult-onset still's diseaseinterleukin-1interleukin-6canakinumabbiological agents
collection	DOAJ
language	Russian
format	Article
sources	DOAJ
author	R. R. Samigullina E. A. Vasilenko V. I. Mazurov
spellingShingle	R. R. Samigullina E. A. Vasilenko V. I. Mazurov A clinical case of adult-onset Still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitors Современная ревматология adult-onset still's disease interleukin-1 interleukin-6 canakinumab biological agents
author_facet	R. R. Samigullina E. A. Vasilenko V. I. Mazurov
author_sort	R. R. Samigullina
title	A clinical case of adult-onset Still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitors
title_short	A clinical case of adult-onset Still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitors
title_full	A clinical case of adult-onset Still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitors
title_fullStr	A clinical case of adult-onset Still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitors
title_full_unstemmed	A clinical case of adult-onset Still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitors
title_sort	clinical case of adult-onset still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitors
publisher	IMA-PRESS LLC
series	Современная ревматология
issn	1996-7012 2310-158X
publishDate	2019-03-01
description	The basis of the clinical picture of adult-onset Still's disease is a triad of symptoms, includingfever, arthralgia/arthritis, and characteristic rash called «Still rash». The first line of therapy includes glucocorticoids, synthetic disease-modifying anti-rheumatic drugs; biological agents, such as tumor necrosis factor a inhibitors and interleukin-6 and interleukin-1 inhibitors, are used in standard therapy-resistant cases.
topic	adult-onset still's disease interleukin-1 interleukin-6 canakinumab biological agents
url	https://mrj.ima-press.net/mrj/article/view/892
work_keys_str_mv	AT rrsamigullina aclinicalcaseofadultonsetstillsdiseaseresistanttotherapywithtumornecrosisfactoralphainhibitorsandinterleukin6inhibitors AT eavasilenko aclinicalcaseofadultonsetstillsdiseaseresistanttotherapywithtumornecrosisfactoralphainhibitorsandinterleukin6inhibitors AT vimazurov aclinicalcaseofadultonsetstillsdiseaseresistanttotherapywithtumornecrosisfactoralphainhibitorsandinterleukin6inhibitors AT rrsamigullina clinicalcaseofadultonsetstillsdiseaseresistanttotherapywithtumornecrosisfactoralphainhibitorsandinterleukin6inhibitors AT eavasilenko clinicalcaseofadultonsetstillsdiseaseresistanttotherapywithtumornecrosisfactoralphainhibitorsandinterleukin6inhibitors AT vimazurov clinicalcaseofadultonsetstillsdiseaseresistanttotherapywithtumornecrosisfactoralphainhibitorsandinterleukin6inhibitors
_version_	1721250261755756544

A clinical case of adult-onset Still's disease resistant to therapy with tumor necrosis factor-alpha inhibitors and interleukin-6 inhibitors

Similar Items